Soligenix, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -1.97%73.511.0%$1662.26m
AMGNAmgen, Inc. -0.45%218.211.3%$912.64m
REGNRegeneron Pharmaceuticals, Inc. 0.12%512.962.6%$838.70m
BIIBBiogen, Inc. 1.29%321.051.5%$803.32m
VRTXVertex Pharmaceuticals, Inc. -1.22%246.611.9%$654.46m
ILMNIllumina, Inc. 2.36%287.623.5%$500.86m
MRNAModerna, Inc. -1.73%31.860.0%$490.05m
ALXNAlexion Pharmaceuticals, Inc. -2.36%96.232.0%$302.00m
AAgilent Technologies, Inc. 2.14%78.331.6%$228.79m
INCYIncyte Corp. -1.07%86.812.5%$215.18m
EXASEXACT Sciences Corp. 1.04%67.0621.0%$180.99m
SGENSeattle Genetics, Inc. 0.54%120.326.1%$157.23m
BMRNBioMarin Pharmaceutical, Inc. -0.06%79.554.3%$148.36m
IMMUImmunomedics, Inc. 6.57%19.6411.9%$133.04m
NVAXNovavax, Inc. -0.76%17.05114.7%$128.79m

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.